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Background: The product of the Bcar1/p130Cas (breast can-
cer resistance/p130Crk-associated substrate) gene causes re-
sistance to antiestrogen drugs in human breast cancer cells
in vitro. To investigate its role in clinical breast cancer, we
determined the levels of Bcar1/p130Cas protein in a large
series of primary breast carcinomas. Methods: We measured
Bcar1/p130Cas protein in cytosol extracts from 937 primary
breast carcinomas by western blot analysis. The levels of
Bcar1/p130Cas protein were tested for associations and
trends against clinicopathologic and patient characteristics,
the lengths of relapse-free survival and overall survival (n =
775), and the efficacy of first-line treatment with tamoxifen
for recurrent or metastatic disease (n = 268). Results: Bcar1/
p130Cas levels in primary tumors were associated with age/
menopausal status and the levels of estrogen receptor and
progesterone receptor. In univariate survival analysis,
higher Bcar1/p130Cas levels were associated with poor re-
lapse-free survival and overall survival (both two-sided P =
.04; log-rank test for trend). In multivariate analysis, a high
level of Bcar1/p130Cas was independently associated with
poor relapse-free survival and overall survival. The response
to tamoxifen therapy in patients with recurrent disease was
reduced in patients with primary tumors that expressed high
levels of Bcar1/p130Cas. In multivariate analysis for re-
sponse, Bcar1/p130Cas was independent of classical predic-
tive factors, such as estrogen receptor status, age/meno-
pausal status, disease-free interval, and dominant site of re-
lapse. Conclusion: Patients with primary breast tumors ex-
pressing a high level of Bcar1/p130Cas protein appear to
experience more rapid disease recurrence and have a greater
risk of (intrinsic) resistance to tamoxifen therapy. Thus,
measurement of Bcar1/p130Cas may provide useful prog-
nostic information for patients with primary or metastatic
breast cancer. [J Natl Cancer Inst 2000;92:120–7]
The breast epithelium is continuously exposed to the steroid
hormone estrogen, which has been implicated in the prolifera-
tion of breast tumor cells and in the progression of breast cancer.
Estrogens act by binding to the nuclear estrogen receptor (ER)
present in the breast epithelial cells. The ER–ligand complex
specifically activates target genes, resulting in a cascade of
events leading to cell proliferation and differentiation (1,2). The
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recent cloning of a closely related ER, ERb (3,4), suggests the
presence of alternative pathways of estrogen signaling. As yet,
little is known about the role of ERb in the development of
human breast cancer (5).
Endocrine therapies have been developed to block the effects
of estrogen on cancer cells or to reduce serum estrogen levels.
Tamoxifen is an antiestrogenic compound that is widely used as
an adjuvant therapy for patients with ER-positive breast tumors
(6). The decision to use endocrine therapy for advanced breast
cancer is based on a number of predictive factors, including ER
or progesterone receptor (PgR) status, age, menopausal status,
disease-free interval, and site of relapse. About 50% of the pa-
tients with advanced breast cancer receiving endocrine treatment
have an objective response or stable disease (no change for >6
months). The rest of the patients have a short period of stable
disease or immediate progressive disease (7). The latter patients
are considered to have intrinsic-resistant disease. However, al-
most all of the responding patients eventually experience disease
recurrence (i.e., acquired resistance). Tamoxifen resistance may
result from multiple mechanisms, and a number of causes have
been suggested, including (epi)genetic alterations, resulting in
ER mutants and splice variants (8–10), and alteration of absorp-
tion, distribution, and metabolism of tamoxifen (11,12). Eluci-
dation of the mechanism(s) of tamoxifen resistance is, therefore,
a comprehensive challenge in cancer biology.
To identify genes involved in hormone-independent growth,
we used the technique of retroviral insertional mutagenesis and
ZR-75-1 cells, a human breast cancer cell line. With this system,
we have identified three loci responsible for breast cancer anti-
estrogen resistance (BCAR) (13–15). The first genomic locus
linked to the antiestrogen drug-resistant phenotype of the cells
that we identified was the BCAR1 locus (13). Characterization
of the BCAR1 gene indicated that it is the human homologue of
the rat-docking protein also known as p130 Crk-associated sub-
strate (p130Cas) (16). p130Cas, which contains an Src homol-
ogy (SH) 3 domain, a proline-rich region, and a substrate do-
main containing multiple SH2-binding motifs, was identified as
a major substrate for protein tyrosine phosphorylation in v-Src-
and v-Crk-transformed cells (17,18) and has been implicated in
a variety of biologic processes, including cell adhesion (19,20),
cell migration (21–23), growth factor stimulation (24), cytokine
receptor engagement (25), and bacterial infection (26,27). Cell
fusion-mediated transfer of the BCAR1 locus and transfection of
BCAR 1/p130Cas complementary DNA into ZR-75-1 cells
demonstrated that overexpression of Bcar1/p130Cas results in
sustained cell proliferation in the presence of antiestrogens (16).
These observations prompted us to investigate the clinical rel-
evance of Bcar1/p130Cas expression by measuring Bcar1/
p130Cas protein in specimens of human breast carcinoma and
testing these data against various characteristics of the patients
and their disease for clinically relevant associations.
MATERIALS AND METHODS
Patients and Tissues
Our study design was approved by the medical ethical committee of the
University Hospital Rotterdam, The Netherlands.
Nonmalignant breast tissues. Breast tissue without specific abnormalities
from 10 women who underwent reduction mammoplasty was used to study
Bcar1/p130Cas levels in normal tissue. Three 50-mm cryosections from these
tissues in TS buffer (i.e., 10 mM Tris–HCl [pH 7.5] and 1% sodium dodecyl
sulfate [SDS]) were sonicated for 10 seconds and boiled for 10 minutes. Lysates
were cleared by centrifugation at 12 000g for 10 minutes at room temperature,
and total protein concentrations were determined with the BCA protein assay
(Pierce Chemical Co., Rockford, IL). Bcar1/p130Cas levels were measured with
the western blotting assay described below.
Primary breast carcinoma. Bcar1/p130Cas levels were determined in cyto-
sol preparations (as described below) from 937 primary breast tumors collected
from 1978 through 1988. Selection of samples was based on the availability of
stored cytosol extracts (in liquid nitrogen), which remained after routine ER and
PgR analyses. Of the 937 patients, 775 (modified mastectomy 4 408 patients;
breast-conserving treatment 4 367 patients) were eligible for analysis of re-
lapse-free survivors and overall survival according to the criteria described else-
where (28). Exclusion criteria were patient tissue that was taken from a biopsy
specimen only (i.e., inoperable stage T4 tumors or tissue that was not obtained
from the primary breast tumor) and patients with insufficient follow-up docu-
mentation. Patients who were referred to our institute more than 100 days after
primary surgery and patients with distant metastasis at the time of primary
surgery [M1 patients; staging according to the International Union Against Can-
cer TNM [tumor–node–metastasis] classification (29)] were excluded from
analyses of relapse-free survival and overall survival, but they were not neces-
sarily excluded from the analysis of response. In fact, we used 36 such patients
in our analysis of the response to tamoxifen therapy in addition to those who
were included according to the criteria described below.
Tumor size, lymph node status, and differentiation grade were gathered from
the reports of regional pathologists. The differentiation grade is not based on a
central pathologic review of all tumor samples and, thus, reflects daily practice.
The median age of the 775 patients at surgery was 57 years (range, 27–90 years).
Radiotherapy was given to 87% of the patients at one or more of the following
sites: the breast/thoracic wall of 549 patients and/or the axilla of 296 patients
and/or the lymph node areas other than the axilla of 328 patients. Adjuvant
chemotherapy (mainly, cyclophosphamide, methotrexate, and 5-fluorouracil
[CMF]) was given to 144 patients, and adjuvant hormonal therapy, either alone
(38 patients) or in combination with CMF (14 patients), was given to 52 patients.
All patients were routinely examined every 3–6 months during the first 5 years
of follow-up and once a year thereafter. Of the 775 patients included in the study
for analysis of relapse-free survival and overall survival, 442 (57%) showed
evidence of relapse during follow-up, and 372 (48%) died. At the end of the
study, 403 patients were alive, with a median follow-up of 105 months (range,
18–175 months). The following characteristics at surgery are shown in Table 1:
tumor size, lymph node status, differentiation grade of the tumor, age, meno-
pausal status, ER status, and PgR status.
Of the 442 patients who relapsed, 232 subsequently received tamoxifen
therapy as a first-line treatment and were included in the analysis of response to
first-line tamoxifen therapy for recurrent disease. The remaining patients were
treated by surgery, radiotherapy, chemotherapy, or other forms of endocrine
therapy or died without further treatment. The following inclusion criteria were
used: patients with advanced disease who were treated with first-line tamoxifen
therapy (40 mg/day) and were not exposed to hormonal treatment at an earlier
stage (hormone naive). This subset was expanded to include the 36 patients
excluded from analyses of relapse-free survival and overall survival. The median
age of the patients with advanced disease at the start of tamoxifen treatment was
63 years (range, 28–91 years). Of these patients, 18% (n 4 48) were premeno-
pausal and 82% (n 4 220) were postmenopausal. The dominant site of disease
was the viscera in 107 patients, the bone in 118, and the soft tissue in 43. After
primary surgery, 50 (19%) patients received systemic adjuvant chemotherapy
(CMF, 41 patients; 5-fluorouracil, doxorubicin [Adriamycin], and cyclophos-
phamide [FAC], nine patients). During the course of their metastatic disease,
60% of the patients were subsequently treated with one or more additional
hormonal treatments (mostly progestins) after disease progression during the
first-line tamoxifen treatment. At the time of analysis, 40 patients were still alive,
with a median follow-up of 38 months (range, 5–88 months), and 228 patients
had died, with a median survival time of 20 months (range, 11 days to 8 years)
after start of tamoxifen therapy. During follow-up but after the start of first-line
endocrine therapy, 252 (94%) of 268 patients had disease progression, with a
median time to disease progression of 5 months (range, 11 days to 6 years).
Patients were examined during endocrine therapy at the outpatient clinic on
average once every 6 weeks and during long-term remission up to once every 12
weeks. Response to treatment, as assessed by standard criteria, was defined as a
patient having an objective response (complete [i.e., the complete disappearance
of all metastases] and partial response) or prolonged stable disease, with a time
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to treatment failure of more than 6 months (30–32). Patients with prolonged
stable disease and patients with a partial response have similar survival prob-
ability (33,34). When there was any doubt, the worst category of response was
chosen. Of the 268 patients who received tamoxifen therapy as first-line treat-
ment for recurrent or metastatic disease, 136 (51%) patients responded (42 had
an objective response and 94 had stable disease). Of the 132 (49%) patients who
did not respond, 17 showed no change in their disease for 6 months or less, and
115 showed progressive disease after treatment began.
Preparation of Cytosolic Extracts From Tumors
Cryopreserved (liquid nitrogen) breast tumor specimens were pulverized with
a microdismembrator as recommended by the European Organization for Re-
search and Treatment of Cancer (EORTC) for determining cytosolic levels of the
ER and PgR proteins (35). The resulting tissue powder was suspended in
EORTC receptor buffer (10 mM K2HPO4, 1.5 mM K2EDTA, 3 mM sodium
azide, 10 mM monothioglycerol, and 10% [vol/vol] glycerol [pH 7.5]). The
homogenate was centrifuged at 100 000g for 30 minutes at 40 °C, and the su-
pernatant fraction (cytosol extract) was obtained and stored in liquid nitrogen
until assayed. Total protein levels in the extracts were determined by use of the
Bradford dye-binding assay (Bio-Rad Protein Assay; Bio-Rad Laboratories, Inc.,
Hercules, CA), with human serum albumin (Kabi Vitrum Diagnostica, Stock-
holm, Sweden) as the standard. ER and PgR levels were determined by a ligand-
binding assay or an enzyme immunoassay as described previously (36). The
cutoff point used to classify tumors as ER or PgR positive was 10 fmol of
receptor protein/mg of cytosol protein.
Western Blot Assay for Bcar1/p130Cas
To determine Bcar1/p130Cas levels in tissue, 5 mg of cytosolic or total extract
protein from tumor tissue, nonmalignant breast tissue, or a cell line standard was
boiled in loading buffer (i.e., 10 mM Tris–HCl [pH 6.8], 1 mM EDTA, 10%
glycerol, 2% SDS, 2.5% 2-mercaptoethanol, and 0.00025% bromophenol blue)
and electrophoretically separated in SDS–6% polyacrylamide gel. Each gel also
contained prestained SDS–polyacrylamide gel electrophoresis molecular weight
markers (Bio-Rad Laboratories) and lysate from the Bcar1/p130Cas-
overexpressing human cell line 4A12 (16) in two concentrations as a standard.
Proteins were transferred to a poly(vinylidene difluoride) membrane (Hybond P;
Amersham Pharmacia Biotech, Buckinghamshire, U.K.) with a semidry trans-
blotter (Owl Scientific Inc., Woburn, MA). After an overnight blocking step at
4 °C in TBST (i.e., 100 mM Tris–HCl [pH 7.4], 1.5 M NaCl, and 0.05% Tween
20) containing 0.6% bovine serum albumin, the blots were incubated with a
1 : 5000 dilution of anti-p130Cas monoclonal antibody generated against rat
p130Cas (Transduction Laboratories, Lexington, KY) for 1 hour. This procedure
was followed by incubation with a 1 : 10 000 dilution of a horseradish peroxi-
dase-conjugated rabbit anti-mouse antibody (Dako, Glostrup, Denmark) for 1
hour. Immunocomplexes were visualized by chemiluminescence (enhanced che-
miluminescence western blotting detection reagents; Amersham Pharmacia Bio-
tech) and exposure to blue-light-sensitive x-ray screen film (CEA, Stra¨ngna¨s,
Sweden). To determine Bcar1/p130Cas protein levels, several exposure times
(45 seconds, 90 seconds, 3 minutes, and 6 minutes) were used for each blot, and
a Bcar1/p130Cas standard (two concentrations) was used as reference. Bcar1/
p130Cas protein levels were scored visually by three investigators (S. van der
Flier, A. Brinkman, and L. C. J. Dorssers) who were not aware of the clinical
data. The consensus score was divided into the four following groups: none 4
no Bcar1/p130Cas protein expression detected on both short and long exposures
of the film (e.g., see Fig. 1, lanes T1 and T9); low 4 no signal on a short
exposure and a weak signal on a long exposure (Fig. 1, lane T4); intermediate 4
a weak signal on a short exposure and a clear signal on a long exposure (Fig. 1,
lanes T2, T3, and T8); and high 4 a clear signal on a short exposure (Fig. 1,
lanes T5, T6, and T7).
Table 1. Relationship of Bcar1/p130Cas expression with patient and tumor characteristics at the time of surgery
Characteristic Total*
Bcar1/p130Cas expression, %
Two-sided PNone Low Intermediate High
Patients, No. 775 33 39 20 8
Age, y .006†
ł40 101 37 41 19 4
40–55 257 33 44 16 7
56–70 270 33 35 21 11
>70 147 27 39 24 10
Menopausal status .04‡
Premenopausal 293 34 43 17 6
Postmenopausal 482 32 37 22 10
Tumor size§ .86\
T1 ł2 cm 294 32 39 19 9
T2 >2–5 cm 372 32 40 20 8
T3/4 >5 cm 97 35 38 20 7
Lymph node status§ .81\
N0 310 33 39 19 9
N1–3 224 33 40 20 7
N>3 232 31 41 20 9
Differentiation grade¶ .01‡
Good/moderate 140 23 45 24 8
Poor 440 37 38 16 8
Missing 195 30 38 24 8
Estrogen receptor status <.001†
Negative 165 52 30 15 3
Positive 606 27 42 21 10
Progesterone receptor status <.001†
Negative 224 45 33 17 5
Positive 535 27 42 21 10
Because of some missing values, numbers do not always add up to 775 patients.
†Wilcoxon-type test for trend.
‡Mann–Whitney U test.
§For tumor size and lymph node status, see (29).
\Kruskal–Wallis test.
¶Based on histologic and cellular characteristics, as stated in the reports of the regional pathologists.
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Statistical Analysis
The strength of the association between Bcar1/p130Cas levels in cytosolic
extracts from tumors (treated as an ordinal variable) and other prognostic vari-
ables (patient or tumor characteristics treated as grouping variables) was tested
with the Mann–Whitney U test or the Kruskal–Wallis test. To test for trends, a
nonparametric test for trend across ordered groups as developed by Cuzick (37)
was used. All P values are two-sided. Two-sided P values of less than .05 were
considered to be statistically significant. Relapse-free survival and overall sur-
vival probabilities were calculated by the actuarial method of Kaplan and Meier
(38). A local disease recurrence (n 4 442), distant spread (n 4 313), or con-
tralateral breast cancer (n 4 37) was considered an event for relapse-free sur-
vival. For the analysis of relapse-free survival, patients who died without a
reported disease recurrence were censored at their date of death. Both univariate
and multivariate analyses were performed with the Cox proportional hazard
model. For missing values, separate dummy variables were created. The assump-
tion of proportional hazards was verified graphically. Relative hazard ratios were
calculated and presented with 95% confidence intervals. For multivariate analy-
sis, a basic model was introduced, including the classical prognostic factors (age,
menopausal status, tumor size, number of positive lymph nodes, ER status, PgR
status, differentiation grade, and systemic adjuvant therapy). Age and meno-
pausal status combined were treated as one variable. The prognostic importance
of Bcar1/p130Cas expression was tested by adding Bcar1/p130Cas to the basic
model. The likelihood ratio test in the univariate Cox regression model was used
to test for differences, and the log-rank test for trend was used to evaluate trends.
The relation with response to therapy was examined with logistic regression
analysis. For analysis of the time to disease progression after the start of tamoxi-
fen treatment, the Cox proportional hazard model was used. All statistical analy-
ses were performed with Stata Statistical Software (release 5.0; Stata Corpora-
tion, College Station, TX).
RESULTS
Detection of Bcar1/p130Cas Protein by Western Blot
Analyses
The anti-p130Cas monoclonal antibody used recognizes the
human Bcar1/p130Cas protein with an apparent molecular mass
of 116 kd, as estimated by SDS–polyacrylamide gel electropho-
resis (16). By analyzing subcellular fractions, we retained the
bulk of Bcar1/p130Cas protein in routinely prepared cytosolic
extracts (Fig. 1), thus enabling the screening of a large number
of breast carcinomas for Bcar1/p130Cas expression. As shown
by western blot analysis, levels of Bcar1/p130Cas protein dif-
fered in different tumors (Fig. 1). Bcar1/p130Cas protein ex-
pression was also evaluated in nonmalignant breast tissue from
10 women. In contrast to malignant tissue, Bcar1/p130Cas pro-
tein was not detected in any nonmalignant breast tissue analyzed
(Fig. 1). To study the possible relationship with relapse-free
survival and overall survival and response to first-line tamoxifen
treatment, the expression levels of Bcar1/p130Cas from breast
tumors were divided into four groups (none, low, intermediate,
and high) based on the intensity of the western blot bands.
Relationship of Bcar1/p130Cas Levels With Patient and
Tumor Characteristics
We compared the levels of Bcar1/p130Cas protein in cyto-
solic extracts from 775 tumors with patient and tumor charac-
teristics (Table 1). Thirty-three percent of the tumors had no
Bcar1/p130Cas protein, 39% had low Bcar1/p130Cas expres-
sion, 20% had intermediate expression, and 8% had high Bcar1/
p130Cas expression. Intermediate and high levels of Bcar1/
p130Cas were more frequently found in tumors from older
patients (P 4 .006). No statistically significant association of
Bcar1/p130Cas levels with tumor size or lymph node status was
observed. Reduced levels of Bcar1/p130Cas expression (P 4
.01) were statistically significantly associated with poorly dif-
ferentiated tumors. Higher Bcar1/p130Cas levels were statisti-
cally significantly associated with ER- and PgR-positive tumors
(P<.001). Expression levels of Bcar1/p130Cas were similar in
tumors from patients who did not receive adjuvant treatment or
who received adjuvant hormonal therapy or chemotherapy with
or without hormonal therapy (x2 4 9.79; df 4 6; P 4 .13).
Bcar1/p130Cas and Relapse-Free Survival and Overall
Survival
We next studied the relationship between the level of Bcar1/
p130Cas protein in primary tumors and the length of relapse-free
survival. We found a statistically significant association of high
Bcar1/p130Cas levels with poor relapse-free survival (log-rank
test for trend; x2 4 4.38; df 4 1; P 4 .04) and poor overall
survival (log-rank test for trend; x2 4 4.01; df 4 1; P 4 .04).
Patients with low and intermediate levels of Bcar1/p130Cas pro-
tein in their primary tumor had similar periods of relapse-free
survival (Fig. 2). On the basis of this observation, we decided to
combine these levels for further analyses. Multivariate analysis
was used to evaluate the possible independent prognostic im-
portance of Bcar1/p130Cas expression in analyses of relapse-
free survival and overall survival (Table 2). We introduced a
basic model that included age, menopausal status, tumor size,
number of positive lymph nodes, and the dichotomized bio-
chemical parameters ER and PgR status. When we added the
Bcar1/p130Cas level as an ordinal variable to the basic models
for relapse-free survival and overall survival, we found that its
expression level contributed to the prognostic information pro-
vided by the classical prognostic factors (Table 2). Thus, in
patients with primary breast cancer, the level of Bcar1/p130Cas
protein is an independent predictor of early recurrence and
death.
Fig. 1. Western blot analysis of protein extracts of human breast carcinomas and
nonmalignant breast tissue. Left panel: Five micrograms of cytosol extracts
from nine primary breast carcinomas (lanes T1–T9) was examined by western
blot analysis with an anti-p130Cas monoclonal antibody (MAb) to measure
Bcar1/p130Cas protein. As a standard, a total lysate from 4A12 cells, a Bcar1/
p130Cas-overexpressing human cell line, was applied at two concentrations.
Two exposure times of the relevant part of the blot are shown, with the position
of the Bcar1/p130Cas band (approximately 116 kd) indicated by an arrowhead.
Short (top) and long (bottom) exposures were used to classify Bcar1/p130Cas
expression as none (lanes N), low (lane L), intermediate (lanes I), or high (lanes
H). Middle panel: Five micrograms of a cell lysate from nonmalignant (normal)
breast tissue was examined by western blot analysis with the p130Cas MAb. A
very long exposure of the blot is shown. A cell lysate from D4E6 cells, a
Bcar1/p130Cas-overexpressing cell line (16), was used as control. The lower
band visible on the blot resulted from cross-reaction with the secondary anti-
body. Right panel: Equivalent amounts of the homogenate and cytosolic (cy-
tosol) and pellet fractions from a primary breast tumor were examined by west-
ern blot analysis with MAb p130Cas.
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Bcar1/p130Cas and Response to Tamoxifen Treatment
Next, we investigated a possible relationship between the
level of Bcar1/p130Cas protein in the tumor and the efficacy of
response to tamoxifen as first-line systemic therapy for recurrent
or metastatic disease. Of the 268 patients who were treated with
tamoxifen, 136 (51%) responded, with a median time to disease
progression of 16 months. The responses to tamoxifen were
Fig. 2. Relapse-free survival of 775 breast carcinoma patients as a
function of the expression level (none, low, intermediate [interm], or
high) of Bcar1/p130Cas protein in the cytosolic extracts of primary
breast carcinomas. The number of patients at risk are indicated. The
survival probability (and their 95% confidence intervals [CIs]) at 48
and 96 months, respectively, are as follows: curve none 4 0.63 (95%
CI 4 0.57–0.69) and 0.50 (95% CI 4 0.44–0.56); curve low 4 0.56
(95% CI 4 0.50–0.61) and 0.42 (95% CI 4 0.36–0.48); curve inter-
mediate 4 0.56 (95% CI 4 0.47–0.63) and 0.44 (95% CI 4 0.35–
0.52); and curve high 4 0.50 (95% CI 4 0.37–0.61) and 0.32 (95% CI
4 0.20–0.44). RHR 4 relative hazard rate; BCAR1/p130Cas 4
Bcar1/p130Cas.
Table 2. Multivariate Cox regression analysis*
Factor
Relapse-free survival Overall survival
Two-sided P RHR (95% CI) Two-sided P RHR (95% CI)
Basic model†
Age/menopausal status .025 .21
Premenopausal‡ 0.76 (0.59–0.99) 0.91 (0.66–1.27)
Postmenopausal‡ 0.95 (0.82–1.10) 1.17 (1.01–1.36)
Postmenopausal versus premenopausal 1.09 (0.71–1.68) 1.01 (0.60–1.70)
Tumor size§ .012 .002
T2 versus T1 1.15 (0.92–1.43) 1.36 (1.05–1.75)
T3/4 versus T1 1.68 (1.23–2.29) 1.95 (1.40–2.73)
Missing versus T1 0.82 (0.33–2.01) 1.59 (0.73–3.47)
Lymph node status§ <.001 <.001
N1–3 versus N0 2.22 (1.66–2.97) 2.37 (1.72–3.26)
N>3 versus N0 3.36 (2.54–4.44) 3.33 (2.46–4.52)
Missing versus N0 2.04 (0.82–5.07) 1.83 (0.73–4.62)
ER status .038 .036
Positive versus negative 1.18 (0.89–1.54) 0.99 (0.75–1.31)
Missing versus negative 5.06 (1.70–15.04) 5.77 (1.83–18.2)
PgR status .76 .025
Positive versus negative 0.92 (0.72–1.18) 0.70 (0.54–0.90)
Missing versus negative 1.04 (0.52–2.09) 0.86 (0.43–1.73)
Systemic adjuvant therapy <.001 .005
Hormonal therapy versus none 0.64 (0.42–0.99) 0.66 (0.42–1.03)
Chemotherapy ± hormonal therapy versus none 0.50 (0.37–0.69) 0.60 (0.42–0.85)
Differentiation grade¶ .004 .26
Poor versus good/moderate 1.30 (1.00–1.70) 1.26 (0.94–1.69)
Missing versus good/moderate 0.90 (0.66–1.23) 1.12 (0.80–1.57)
Addition to basic model
Bcar1/p130Cas# .03 .04
L + I versus none 1.20 (0.97–1.50) 1.24 (0.98–1.57)
High versus none 1.62 (1.13–2.32) 1.65 (1.11–2.46)
*RHR 4 relative hazard rate; CI 4 confidence interval; ER 4 estrogen receptor; PgR 4 progesterone receptor; L 4 low; I 4 intermediate.
†Basic model included age/menopausal status (combined), tumor size, lymph node status, ER status, PgR status, systemic adjuvant therapy, and differentiation
grade.
‡Age in decades tested separately for premenopausal and postmenopausal patients.
§For tumor size and lymph node status, see (29)
\Chemotherapy with (n 4 14) and without (n 4 144) hormonal therapy.
¶See Table 1.
[Added to basic model. Final model included 775 patients.
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similar in the subgroups with no (53%), low (50%), or interme-
diate (58%) levels of Bcar1/p130Cas protein in their tumors,
whereas the response in patients with a high level of Bcar1/
p130Cas in their tumors was lower (33%). However, the objec-
tive response was similar in all subgroups. The observed lower
response rate in the high Bcar1/p130Cas subgroup is thus a
reflection of a reduced number of patients with long-term stable
disease. The tumors with high Bcar1/p130Cas levels were pre-
dominantly ER positive (29 [97%] of 30 tumors); fewer patients
in the other subgroups had ER-positive tumors (approximately
85%). Again, the subgroups with low or intermediate Bcar1/
p130Cas expression were combined. When analysis was per-
formed on 230 ER-positive tumors only, there was a statistically
significant association between a poor response to tamoxifen
treatment and high expression of Bcar1/p130Cas (high 4 34%;
none 4 61%; P 4 .02). In the multivariate analysis for response
to treatment, Bcar1/p130Cas levels were corrected for meno-
pausal status, relapse-free interval, and ER status (as a dichoto-
mized variable). Independent predictors of poor response were
premenopausal status, short disease-free interval, ER-negative
status of the tumor, and high levels of Bcar1/p130Cas (Table 3).
In a separate analysis, we included ER status as a continuous
variable (log transformed) and found that a high level of Bcar1/
p130Cas expression, compared with no expression, was still
associated with a poor response to tamoxifen (P 4 .01). How-
ever, these results should be interpreted with some caution be-
cause we did not correct for multiple comparisons. An explana-
tion for the observed differences between univariate and
multivariate analyses could be the strong relation between an
ER-positive status of the tumors and high Bcar1/p130Cas ex-
pression, which was corrected in the multivariate analysis.
The association between Bcar1/p130Cas expression and time
to disease progression of the disease after the start of systemic
treatment with tamoxifen, as analyzed by Cox regression analy-
sis, was not statistically significant. Nevertheless, with increas-
ing expression levels of Bcar1/p130Cas in the primary tumor,
the median progression-free survival time of the patients was
reduced substantially from 7 months (none, low, and intermedi-
ate expression) to 3 months (high expression).
DISCUSSION
An understanding of the molecular mechanisms of tamoxifen
resistance should contribute to the determination of optimal
therapies for individual patients. We have proposed that genetic
alterations in the tumor cells allow these cells to escape anties-
trogen therapy (13). With our model system, we have identified
the BCAR1 gene and shown that it can confer tamoxifen-
resistant cell proliferation when overexpressed in vitro (16). In
this study, we investigated a possible association of the expres-
sion of Bcar1/p130Cas protein in primary human breast carci-
noma with disease progression and response to tamoxifen
therapy. Bcar1/p130Cas expression was found to vary consid-
erably between the breast carcinomas, and relatively high Bcar1/
p130Cas expression was detected in 8% of the breast primary
tumors tested. In contrast, Bcar1/p130Cas protein was not de-
tected in nonmalignant breast tissue samples by western blot
analysis. Immunohistochemical analysis with the same antibody
has confirmed that the Bcar1/p130Cas protein detected in cyto-
solic extracts of tumors by western blot analysis is localized in
tumor cells and that the expression of Bcar1/p130Cas in normal
breast tissue is observed in the limited numbers of ductal epi-
Table 3. Logistic regression analysis of response to tamoxifen therapy*
No. of
patients
Univariate analysis Multivariate analysis
%† Two-sided P Odds ratio 95% CI Two-sided P
All patients 268 51
Menopausal status
Premenopausal 48 44 1
Postmenopausal 220 53 .02 2.54 1.26–5.09 .01
Dominant site of relapse
Soft tissue 43 53
Bone 118 51 .77 —
Viscera 107 50 .66
Relapse-free survival, mo
<12 74 30 1
ø12 194 59 <.001 3.29 1.79–6.06 <.001
ER status
Negative 37 22 1
Positive 230 56 <.001 4.47 1.89–10.59 <.001
PgR status
Negative 64 36
Positive 196 56 .01 —
Bcar1/p130Cas level‡
None 72 53 1
L + I versus none 166 53 .97 0.90 0.49–1.66 .74
High versus none 30 33 .08 0.38 0.14–0.98 .04
*CI 4 confidence interval; ER 4 estrogen receptor; PgR 4 progesterone receptor; L 4 low; I 4 intermediate. There was one missing value for ER and eight
for PgR.
†Percent overall response 4 percentage of patients with complete response, partial response, or stable disease for more than 6 months.
‡Distributions of Bcar1/p130Cas expression in tumors of the group of 36 patients included were not different from those of the remaining 232 patients selected
from the disease-free survival analysis (Table 1) (x2 4 2.80; df 4 3; P 4 .42).
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thelial cells and not in the abundant stroma (van der Flier S,
Dorssers LCJ, van der Kwast TH: unpublished results).
Analysis of the expression of Bcar1/p130Cas protein in pri-
mary breast cancer has led to two distinct observations. First,
relatively high expression of Bcar1/p130Cas in primary breast
tumors is associated with a rapid recurrence of the disease. The
risk of relapse was 62% greater for patients whose tumors had
high levels of Bcar1/p130Cas than for patients whose tumors
had undetectable levels of Bcar1/p130Cas protein. Multivariate
analysis showed that a high level of Bcar1/p130Cas in the pri-
mary tumor was associated with an early relapse, independent of
the classical prognostic parameters. Consequently, a high level
of Bcar1/p130Cas protein in primary tumor extracts (compared
with no detectable Bcar1/p130Cas in their primary tumor) is
statistically significantly associated with a 65% reduced overall
survival of patients. These results indicate that tumors with high-
level expression behave more aggressively than tumors with
low-level or undetectable expression. This association may be
explained biologically by the involvement of Bcar1/p130Cas in
cellular migration and invasion (21–23). These properties sug-
gest a higher risk of early dissemination of individual cells from
the subgroup of tumors with high-level expression of Bcar1/
p130Cas.
Second, high-level expression of Bcar1/p130Cas in the pri-
mary tumors (compared with tumors with no detectable Bcar1/
p130Cas expression) is associated with a poorer response to
first-line tamoxifen treatment. This observation is consistent
with our findings with the in vitro model system; i.e., Bcar1/
p130Cas overexpression resulted in antiestrogen resistance in
cell lines (13,16). Tamoxifen generally induces an objective re-
sponse or stable disease in about half of the patients with ER-
positive primary tumors and recurrent or metastatic disease
(39,40). The other patients who have ER-positive primary tu-
mors experience immediate disease progression because of in-
trinsic resistance to tamoxifen. In our study, 67% of the patients
with a relatively high level of Bcar1/p130Cas protein in their
primary tumors did not respond to tamoxifen. This finding may
explain some of the clinically observed intrinsic resistance to
tamoxifen. Because these tumors are generally ER positive and
the patients are, thus, eligible for tamoxifen therapy, Bcar1/
p130Cas levels could be used by physicians to determine which
patients may not respond to tamoxifen. Therapeutic decisions
may benefit from more precise quantification of Bcar1/p130Cas
protein levels in primary tumors. Because several lines of evi-
dence show that development of resistance to antiestrogen
agents is not always associated with the loss of ER expression in
the tumor cells (41–43), the association of the high levels of
Bcar1/p130Cas in ER-positive primary tumors that have a poor
response to tamoxifen suggests the possibility of an alternative
pathway to bypass ER-mediated cell proliferation.
Despite many reports on Bcar1/p130Cas function in various
cell systems, few clues are available about the pathway leading
to the altered proliferation control in our cells (44,45). Changes
in adhesion and migration may affect cell proliferation, but the
precise pathway in breast epithelial cells is yet unclear. Bcar1/
p130Cas protein can be phosphorylated on tyrosine residues and
can associate with many proteins that contain SH2 domains
(44,46,47). In addition, the SH3 domain of Bcar1/p130Cas may
also associate with other proteins through proline-containing tar-
get sequences (17,48,49). Bcar1/p130Cas serves as an adapter
protein to contact proteins that participate in various cellular
processes and is dependent on the availability, activation status,
and affinity of its partners. These interactions are part of a cas-
cade of signaling events leading to the regulation of gene ex-
pression and the regulation of the cell cycle. Because Bcar1/
p130Cas appears to have a role in the progression of clinical
breast cancer, elucidation of this critical pathway could contrib-
ute valuable information for the development of new treatment
strategies for antiestrogen-resistant breast cancer.
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